Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | VG2025 |
Synonyms | |
Therapy Description |
VG2025 is an oncolytic herpes simplex virus-1 (HSV-1) engineered to express IL-12 and IL-15/IL-15Ralpha, which potentially induces an antitumor immune response (PMID: 36938544). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VG2025 | VG-2025|VG 2025 | VG2025 is an oncolytic herpes simplex virus-1 (HSV-1) engineered to express IL-12 and IL-15/IL-15Ralpha, which potentially induces an antitumor immune response (PMID: 36938544). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06365918 | Phase I | VG2025 | Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis | Not yet recruiting | USA | 0 |
NCT05266612 | Phase I | VG2025 | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Subjects With Advanced Malignant Solid Tumors | Recruiting | USA | 0 |